EU-Canada CETA: Pharma ingredient recognition update
The EU Council adopted Decision 2026/1070 on 5 May 2026, setting the EU's negotiating position within the CETA Joint Committee on how active pharmaceutical ingredients (APIs) are classified and recognized under the mutual GMP (good manufacturing practices) compliance agreement between Canada and the EU. The decision amends Annex 1 to the CETA Protocol on pharmaceutical mutual recognition, clarifying which APIs qualify as medicinal products or drugs under the agreement's scope.
Photo: Daniel Trylski / PexelsEU-Canada CETA: Pharma ingredient recognition update
On 5 May 2026, the EU Council adopted Decision (EU) 2026/1070 establishing the European Union's position for discussion within the CETA Joint Committee regarding active pharmaceutical ingredients (APIs) under the Comprehensive Economic and Trade Agreement between Canada and the EU.
What changed
The decision concerns the treatment of active pharmaceutical ingredients as medicinal products or drugs listed in paragraph 2 of Annex 1 to the Protocol on the mutual recognition of the compliance and enforcement programme regarding good manufacturing practices for pharmaceutical products. This protocol is part of the broader CETA framework that streamlines regulatory approval and manufacturing standards between Canadian and EU pharmaceutical producers.
Who is affected
This decision affects pharmaceutical manufacturers, active ingredient suppliers, and exporters trading APIs between the EU and Canada. Companies that produce, source, or import active pharmaceutical ingredients from Canada—or export EU-manufactured APIs to Canada—will be subject to the clarified classification rules. The mutual GMP recognition protocol reduces duplicate inspections and accelerates time-to-market for pharmaceutical products on both sides, provided the APIs meet the agreed definition of "medicinal products or drugs."
Substance of the amendment
The Council decision sets out the EU's formal position ahead of CETA Joint Committee discussions. By amending Annex 1, paragraph 2, the decision clarifies which active pharmaceutical ingredients fall within the scope of mutual GMP recognition. This eliminates ambiguity that may have previously required separate regulatory pathways for certain APIs or created uncertainty in cross-border supply chains.
While the source document does not detail the specific APIs added or removed, the amendment directly affects:
- Import / export classification: APIs must be correctly identified under the amended annex to qualify for streamlined mutual recognition.
- Manufacturing compliance: Facilities producing covered APIs can rely on mutual GMP recognition rather than undergoing duplicative inspections in both jurisdictions.
- Supply-chain planning: Companies must verify API eligibility under the new annex before committing to Canada-EU trade arrangements.
The CETA Joint Committee will formally adopt this position; member states and industry should anticipate that the amendment will take effect following committee consensus.
What this means for shippers
Pharmaceutical exporters and API suppliers must confirm that their active ingredients align with the amended Annex 1, paragraph 2 definition before shipment. Failure to verify classification could result in clearance delays or loss of mutual GMP recognition benefits. Review your APIs with your regulatory affairs team immediately and request current CETA Joint Committee guidance from EU customs authorities. Check HS chapters 29-30 import/export declarations for accuracy against the updated annex.
